Observational studyTranslational vision science & technology2026
Relationship Between Omega-3 Fatty Acids and Glaucoma Risk in Patients With Dry Eye Disease: A Multinational Retrospective Cohort Study.
Observational study in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate whether omega-3 fatty acid supplementation is linked to a reduced glaucoma risk in individuals with dry eye disease. Methods: This retrospective cohort study included adults with dry eye disease from a multinational database between 2013 and 2023. Individuals who received omega-3 were classified into the omega-3 group, and individuals who never received omega-3 were defined as the control group. The omega-3 and control groups were 1:1 propensity score matched for age, sex, race, smoking status, comorbidities, and corticosteroid use. Incident total glaucoma, ocular hypertension, primary open-angle glaucoma (POAG), normal-tension glaucoma, primary angle-closure glaucoma, and the use of first-line glaucoma medications were observed across a 5-year follow-up period. Results: A total of 14,168 participants with dry eye disease were included in the final analysis. Compared with the control group, individuals who received omega-3 fatty acid prescriptions experienced lower risks of total glaucoma (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.42-0.54), ocular hypertension (HR, 0.57; 95% CI, 0.43-0.75), POAG (HR, 0.45; 95% CI, 0.33-0.63), normal-tension glaucoma (HR, 0.41; 95% CI, 0.19-0.88), primary angle-closure glaucoma (HR, 0.45; 95% CI, 0.21-0.94), and the use of first-line glaucoma medications (HR, 0.65; 95% CI, 0.53-0.80). The lower risks of ocular hypertension and POAG associated with omega-3 use remained consistent across those aged 60 years or older, females, Whites, and other demographic categories. Conclusions: Omega-3 fatty acid supplementations may have the potential to decrease glaucoma risk in individuals with dry eye disease. Translational Relevance: Clinically, omega-3 supplementation in patients with dry eye disease may decrease disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.